CanaQuest have received a licence to sell cannabis

CanaQuest

CanaQuest have received a purchase/sales licence with a provision to apply for import and export permits for cannabis.

CanaQuest, a company developing proprietary health products and nutraceuticals utilising cannabinoid and botanical oil extracts. CanaQuest has obtained a cannabis purchase/sales licence, with a provision to apply for import/export permits for cannabis as permitted under the Health Canada Cannabis Act.

“As a licence holder under the Cannabis Regulations, our company can now target the introduction of our first proprietary Cannabis THC and Botanical formulation, Mentabinol™ after December 17th., 2019.” Paul Ramsay, Co-Founder and President of CanaQuest stated. “The research and pre-clinical trials have positioned us to introduce our novel THC formulation to provide a better alternative for recreational and medicinal consumers today. Our goal is to make all consumers of THC products (recreational or medical), who are concerned about the short term and long term negative psychotic effects of THC, aware that our products exist. There is 13 years of research that has led to this amazing discovery.” Ramsay further stated.

The company’s competitive advantage comes from Intellectual Property developed under its sponsored research contract with Western University. Through this partnership with Dr. Laviolette, a scientific veteran with over 13 years of research in the field of mental health and cannabis, plus a dedicated scientific team of 12 scientists and Western University, CanaQuest has a definitive competitive advantage in developing Research and Science based formulations for better THC and CBD experiences. The completed pre-clinical trials at the Western University lab has demonstrated exciting results and has put the Company in a position to introduce CanaQuest’s novel THC formulation at the inception of the Edible and Extract marketplace. Additionally, the scientific data and the beneficial results of our proprietary CBD-based formulation is in the final stage and we anticipate introduction of this new formulation into the marketplace in the very near future.

The use of marijuana is known to cause neuronal, molecular and neuropsychiatric side effects. This complicates the use of marijuana for medical treatment. Δ-9-tetrahydrocannabinol (THC) is the primary psychoactive compound in marijuana (MJ). As demonstrated in both clinical and pre-clinical research, at Western University in London, Ontario, Canada. THC is associated with a wide range of deleterious

LEAVE A REPLY

Please enter your comment!
Please enter your name here